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ABSTRACT
This article describes the construction of a set of
versatile expression vectors based on the
In-Fusion
TM cloning enzyme and their use for high-
throughput cloning and expression screening.
Modifications to commonly used vectors rendering
them compatible with In-Fusion
TM has produced
a ligation-independent cloning system that is
(1) insert sequence independent (2) capable of
cloning large PCR fragments (3) efficient over a
wide (20-fold) insert concentration range and (4)
applicable to expression in multiple hosts. The
system enables the precise engineering of (His6-)
tagged constructs with no undesirable vector or
restriction-site-derived amino acids added to the
expressed protein. The use of a multiple host-
enabled vector allows rapid screening in both E.
coli and eukaryotic hosts (HEK293T cells and insect
cell hosts, e.g. Sf9 cells). These high-throughput
screening activities have prompted the develop-
ment and validation of automated protocols for
transfection of mammalian cells and Ni-NTA protein
purification.
INTRODUCTION
The Oxford Protein Production Facility (OPPF) is a
structural proteomics facility funded to produce high
quality structural data for proteins from a diverse range of
host organisms, including viruses, bacterial human
pathogens and human proteins associated with the
aetiology of human diseases such as cancers. As such,
the OPPF target list contains many proteins that may be
viewed as problematic to express and crystallize. In order
to investigate these proteins either in large numbers or to
investigate, in parallel, many multiple domains of smaller
numbers of these proteins, a highly eﬃcient cloning and
expression screening strategy was required.
The prime characteristics of this process must be:
(1) The ability to clone genes encoding proteins, or
domains thereof, in a rapid and reliable parallel or
high-throughput (HTP) fashion.
(2) The ability to accurately determine the ﬁnal con-
structs without the addition of extraneous/vector or
restriction-site-derived amino acids to the expressed
protein.
(3) The process must be versatile in terms of insert
sequence independence.
(4) The process would preferably be single step, to give
rapid and cost-eﬀective vector construction.
(5) The constructs should be suitable for expressing
proteins from multiple hosts, i.e. a single vector
capable of expression in E. coli, mammalian cell lines
(e.g. HEK293T cells) and insect cell lines (e.g. Sf9
cells).
(6) The expressed proteins must be capable of puriﬁca-
tion in HTP mode, i.e. they must all be fused to a
common aﬃnity puriﬁcation ‘tag’ which may be
removed, if desired, by enzymatic digest prior to
crystallization.
(7) The process should be amenable to automation.
Two options are available for constructing the expres-
sion vectors required for protein production, namely
ligation-dependent and ligation-independent cloning. The
former uses restriction enzyme digestion in combination
with DNA ligation to produce the vectors, whereas the
latter utilizes either some form of recombination or the
production and annealing of single-stranded overhangs,
to avoid the need to restriction digest the input DNA
insert. Typically, in both cases the starting DNA is a PCR
product corresponding to a complete open reading frame
(ORF), or domains thereof, produced from either a
genomic or cDNA template. The PCR primers
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the sequences required for ligation-independent cloning
(LIC) reactivity. By using rare cutting restriction enzyme
sites, ligation-based cloning has been used eﬀectively for
semi-automated high-throughput cloning (1). However,
most projects have adopted ligation-independent cloning
for the obvious reason that it is independent of the input
sequence (2). A number of ligation-independent cloning
methods are commercially available but these require
either multiple rounds of cloning or substantial prepara-
tion of inserts and vector prior to cloning. In addition,
these ligation-independent methods, without exception,
introduce extra codons into the sequence. These are either
predeﬁned, for example the att recombination sites in the
2-step Gateway
TM system (InVitrogen, Paisley, UK), or
may be composed from only three of the four bases, where
the fourth base acts as a ‘lock’ during single-strand
production by the 30 to 50 processing activity of T4
polymerase, for example ligation-independent cloning
[LIC—see (3,4) and also commercially available as the
Radiance
TM system Novagen, Nottingham, UK].
The heterologous expression of large, multi-domain
mammalian or viral proteins in E. coli can be problematic,
often producing either very low yields of the target protein
or miss-folded protein, targeted to inclusion bodies. These
problems highlight the necessity for expression screening
in more than one host type (e.g. mammalian or insect cells
in addition to E. coli). The current HTP cloning and
expression platforms only accommodate this by the use of
multiple host-speciﬁc vectors.
The limitations of existing systems led us to the
development of a ligation-independent cloning method
that satisﬁes our pipeline requirements and cloning
speciﬁcations by utilizing the unique properties of the
commercially available In-Fusion
TM enzyme (Clontech–
Takara Bio Europe, St. Germain en Laye, France). We
have produced a versatile suite of vectors for the
expression of proteins or protein domains without, or
with minimal, extraneous recombination site, or vector-
derived amino acids added to the expressed product. The
vectors described here utilize multiple promoter systems
such that a single construct may be screened for expression
in E. coli, mammalian or insect hosts, thereby avoiding the
need to make multiple, host-speciﬁc, vectors for each
target. In combination with automated liquid handling,
we show that the method enables rapid one-step cloning
and rapid expression screening of recombinant proteins
in E. coli, mammalian cells and insect cells (from
baculovirus).
MATERIALS AND METHODS
Vector construction and preparation
The three-promoter vector pTriEx2 (Novagen) was used
as the basis for construction of the pOPIN series of
expression vectors (Table 1). The In-Fusion
TM-ready
vectors described here include fusion tags for N-His6
plus a 3C cleavage site (5), N-His6-Glutathione-S-
Transferase (GST) plus a 3C cleavage site, N-His6-
Maltose Binding Protein (MBP) plus a 3C cleavage site,
a C-terminal Lys-His6 or a secretion leader sequence
in combination with C-terminal LysHis6. All of the
N-terminal fusion tags are removable with the use of 3C
protease and the histidine residues of the C-terminal
tags are removable by Carboxypeptidase A to leave only
the C-terminal lysine (6).
To enable blue/white screening of recombinant clones
(blue colonies indicate the presence of non-linearized/
non-recombinant parental vector) the lacZ insert from
intact pDNR-Dual (Clontech–Takara Bio Europe) was
ampliﬁed using KOD Hi-Fi polymerase according to the
manufacturer’s instructions (Novagen) and the following
primer pairs: Efwd: 50-GAGATATACCATGGCACACC
ATCACCACCATCACAGCAGCGGTACCGTCGACC
CGACTG GAAAGCG-30 versus Erev: 50-ACTTAGTGA
TGGTGATGGTGATGTTTAAACTGGTCTAGAAAG
CTTGGCGCC-30 Ffwd: 50-GAGATATACCATGGCAC
ACCATCACCACCATCACAGCAGCGGTCTGGAAG
TTCTGTTTCA GGGTACCGTCGACCCGACTGGAA
AGCG-30 versus Frev: 50-ACTTAGTGATGGTGATGG
TGATGTTTAAACTGGTCTAGAAAGCTTGGCGC
C-30.
PCR products were puriﬁed by agarose gel electropho-
resis and gel extraction (Geneclean–Bio101, Morgan
Irvine, CA, US). Products E and F were extended 30
by ampliﬁcation versus MscIrev primer: 50-ccacaccagccac-
caccttctga-30 with pTriEx2 as template.
The extended products E and F were puriﬁed and
digested with NcoI before ligation into NcoI/MscI cut
pTriEx2. Ligation products were transformed into TAM1
cells (Activ Motif, Rixensart, Belgium) and screened for
b-galactosidase activity on LB Agar plates supplemented
with 50mg/ml carbenicillin/0.2% w/v X-Gal and 1mM
IPTG. Colonies expressing b-galactosidase activity were
picked, grown overnight in 1.5ml LB supplemented with
the appropriate antibiotic and the resulting plasmids
extracted by standard methods.
pOPINE was created by ligation of the NcoI-digested
extended product E into NcoI/MscI-cut pTriEx2.
pOPINF  was created by ligation of the NcoI-digested
extended product F into NcoI/MscI-cut pTriEx2.
pOPINF was then created by the deletion of the sequence
encoding the C-terminal Lys-His6 tag from pOPINF  by
the ligation of a phosphorylated primer duplex into PmeI/
MscI-cut pOPINF*: TriEx-CH6fwd: 50-GTGATTAACC
TCAGGTGCAGGCTGCCTATCAGAAGGTGGTGG
CTGGTGTGG-30 TriEx-CH6rev: 50-CCACACCAGCC
ACCACCTTCTGATAGGCAGCCTGCACCTGAGGT
TAATCAC-30.
pOPINF was derived in order to increase the eﬃciency
of cloning of N-His6-3C pOPINF  constructs by deletion
of the sequence encoding the C-terminal Lys-His6 tag as,
in a small number of In-Fusion
TM reactions with
pOPINF  a ‘fusion’ of the sequences encoding both N-
and C-terminal His6 tags was observed (data not shown).
pOPING was generated by ampliﬁcation of the
m-phosphatase secretion leader sequence from pHLsec
(7) using sigpepfwd: 50-CAAGCTTGCCACCATGGGG
ATC-30 and sigpeprev: 50-CGGGGTACCGGTTTCAGC
TACGCAAC-30 primers. The resulting 113bp PCR
product was gel puriﬁed, digested with NcoI and
e45 Nucleic Acids Research, 2007, Vol. 35, No. 6 PAGE2 OF12KpnI enzymes and ligated into NcoI and KpnI-cut,
and puriﬁed, pOPINE (this digest removes the N-His6
site insert from pOPINE). This vector encodes
the MGILPSPGMPALLSLVSLLSVLLMGCVA
Y
ETG
secretion leader sequence (where
Y
indicates the cleavage
site for the eukaryotic signal peptidase enzyme).
pOPINJ was generated by ampliﬁcation of the N-His
GST sequence from pDESTH6N15 (derived from the
Gateway
TM GST vector, pDEST15, Berrow unpublished
data) using the following primers: pOPIN-GST-fwd: 50
GAATTCCATGGCACATCACCATCACCATCACAT
GTCCCCT 30 pOPIN-GST-rev: 50 CGACGGTACCC
TGAAACAGAACTTCCAGACCGCTGCTCAGATCC
GATTTTGGAGGATG 30 The resulting  700bp PCR
product was gel puriﬁed, digested with NcoI and KpnI,
re-puriﬁed and ligated into NcoI and KpnI-cut pOPINE
to produce pOPINJ. This vector encodes an N-terminal
His6-GST-3C cleavable tag: MAHHHHHHSSG-GST-
SSGLEVLFQ
Y
GP...(where
Y
indicates the cleavage
sites for 3C protease).
Similarly pOPINM was generated by ampliﬁcation of
the MBP sequence from pMAL2c (NEB, Hitchin,
Hertfordshire, UK) using the following primer pairs
MBPinﬀwd: 50 ACCATCACAGCAGCGGCATG
AAAATCGAAGAAGGTAAACTGG 30 and MBP
SSG 3C rev: 50 GTCGACGGTACCCTGAAACA
GAACTTCCAGACCGCTGCTAGTCTGCGCGTCTT
TCAGGGC 30 The resulting  1200bp PCR product was
gel puriﬁed and then extended 30 by PCR using pOPINE
as template and LACZþ30INF REV: 50 CTGGTCTAG
AAAGCTTGGCGCCATTCGCCATTCAG 30 as the
reverse primer.
The resulting  1500bp PCR product was then gel
puriﬁed and In-Fused into NcoI and HindIII-cut
pOPINE (normal NcoI-KpnI cloning of this fragment
was not thought possible due to the presence of an
internal NcoI site, although recent checking of the
pOPINM sequencing data reveals that the NcoI site has
been previously removed c.f. the sequence available at
NEB).
This vector encodes an N-terminal His6-MBP-3C
cleavable tag: MAHHHHHHSSG-MBP-SSGLEVL
FQ
Y
GP...(where
Y
indicates the cleavage sites for 3C
protease).
For full details of the fusion tags contributed by these
vectors see Table 1, for a summary of the construction of
these vectors see Figure 1.
The pTriEx2 vector contains the hybrid CMV and
Chicken b-actin promoter/enhancer combination (CAG)
promoter that has been reported to give higher expression
levels when compared to those vectors (e.g. pTriEx4)
using CMV-derived promoter and enhancer (8). In
addition this vector contains a Kozak consensus sequence
(9) for eﬃcient initiation of translation in eukaryotic
hosts. The presence of the p10 baculoviral promoter and
the ﬂanking lef2 (ORF 603) and ORF1629 baculoviral
recombination sites allow the construction of recombi-
nant baculoviruses and, ﬁnally, a T7 polymerase promoter
with lacO operator oﬀers high level inducible expression
in E.coli harbouring the  (DE3) prophage (10).
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sequencing (MWG Biotech, London, UK) before large-s-
cale plasmid preparations were performed. Prior to their
use in In-Fusion
TM reactions, pOPINF, pOPINJ and
pOPINM vectors were prepared by digestion with KpnI
and HindIII, pOPINE by digestion with NcoI and PmeI
and pOPING by digestion with KpnI and PmeI. All
restriction digests were followed by agarose gel electro-
phoresis, gel extraction and puriﬁcation before elution in
10mM Tris pH 8.0 buﬀer. Linearized vectors were stored
at  208Ci n1 0mg aliquots (equivalent to one 96-well plate
of In-Fusion
TM reactions).
For full details of the fusion tags contributed by the
pOPIN vectors see Table 1, for a summary of the
Figure 1. Vector derivations and maps. Derivation of the pOPIN vectors from pTriEx2. PCR fragments were prepared as described in the Materials
and methods section and either ligated into the pTriEx2 vector or inserted by In-Fusion
TM. In cases where the pOPIN vector is not directly
derivatized from pTriEx2, the intermediate vector is also shown. Features of the pTriEx2 vector retained in the pOPIN vector suite are: T7/lacO
promoter/operator and terminator for inducible expression in E. coli harbouring the  (DE3) prophage, CMV Enhancer/Chicken b-actin promoter
and rabbit b-globin polyA site for eﬃcient expression in mammalian hosts, p10 baculoviral promoter and 50 UTR/ORF603 and ORF 1629 for
eﬃcient expression from/recombination into baculovirus respectively. The high-copy pUC origin of replication and b-lactamase (Ampicillin resistance
marker) gene allow high-copy production of the vector in E. coli.
e45 Nucleic Acids Research, 2007, Vol. 35, No. 6 PAGE4 OF12construction of these vectors see Figure 1. and
the Genbank Accession Numbers for these vectors are
as follows... EF372394 (pOPING), EF372395,
(pOPINJ), EF372396 (pOPINM), EF372397 (pOPINE),
EF372398 (pOPINF).
In-Fusion
TM cloningof PCR products
The appropriate primer extensions were used to
enable In-Fusion
TM cloning into the prepared pOPIN
vectors to derive the desired His6-tagged proteins/
constructs (see Table 1 for primer extension sequence
details). PCR was performed in 50ml reaction mixes using
KOD Hi-Fi polymerase according to the manufacturer’s
instructions (Novagen) with 30pmol of each forward and
reverse primers, appended with the In-Fusion
TM exten-
sions as appropriate, and either 1ml of the appropriate
genomic DNA (50ng/ml) or 1ml of plasmid DNA (100ng/
ml) as template per reaction. The resulting PCR products
for the Neisseria spp. test set were separated by electro-
phoresis on a 1.25% w/v agarose Tris/Borate/EDTA gel,
visualized with SybrSafe
TM (InVitrogen) and puriﬁed
from the gel using the QIAquick
TM 96 kit modiﬁed for
gel extraction (Qiagen, Crawley, West Sussex, UK).
Puriﬁed PCR products were eluted from the
QIAquick
TM 96 plates in 50ml of Buﬀer EB, 10mM Tris
pH 8.0 buﬀer and yields assessed by gel electrophoresis.
All other PCR products were puriﬁed using AMPure
magnetic beads (Beckman-Coulter, High Wycombe,
Buckinghamshire, UK) according to the manufacturer’s
instructions, eluted in 50ml of EB buﬀer (10mM Tris pH
8.0) and yields assessed by gel electrophoresis.
About 5ml of puriﬁed PCR product (range 10–200ng in
total) and 100ng of the appropriately linearized pOPIN
vector were mixed in the wells of an In-Fusion
TM Dry-
Down 96-well plate and incubated at 428C for 30min. All
reactions were diluted 1:5 with T.E. Buﬀer (10mM Tris
pH 8.0, 1mM EDTA) and 5ml used to transform
OmniMaxII T1-phage resistant cells (Invitrogen) in
96-tube format. Transformants were selected by plating
on 24-well culture plates containing 1ml of LB Agar/well,
supplemented with the appropriate antibiotic/0.02% w/v
X-Gal and 1mM IPTG, and incubation overnight at
378C. Generally, if cloning is successful, 90–100% of the
colonies will be white, although this is entirely dependent
on the quality of the initial batch linearization of the
vectors as blues represent the undigested parental vector.
White colonies (four per vector/insert combination) were
used to inoculate 1.5ml LB supplemented with the
appropriate antibiotic in deepwell, 96-well plates. The
cultures were grown overnight at 378C, with shaking at
200r.p.m., before harvesting by centrifugation at 5000g
for 10min at 48C, pelleted cells were then used for plasmid
preparation. Plasmids speciﬁcally for use in E. coli
expression trials were prepared from the E. coli cultures
in 96-well format using a QIAgen BioRobot 8000 and
QIAgen Turboprep kits, according to the manufacturer’s
instructions (Qiagen). Plasmids used for transfection into
either HEK293T or Sf9 cells were prepared under sterile
conditions in a Class 2 ﬂow cabinet using Wizard SV96
kits according to the manufacturer’s instructions
(Promega, Southampton, UK) and a QiaVAC96 manifold
(Qiagen). Typically the plasmids prepared with the Wizard
SV96 kits had a concentration of 125ng/ml of DNA and
an A260/280 ratio of  2.0. The resulting plasmids were
screened using the PCR protocol described previously
except that the forward primer in each case was replaced
by a standard T7 forward primer (50-TAATACGACTC
ACTATAGGG-30), PCR products were analysed by
electrophoresis on a 1.25% w/v Agarose Tris/Borate/
EDTA gel.
Expression in E. coli
PCR veriﬁed expression constructs were transformed
into either B834 (DE3) or Rosetta(DE3)LysS E. coli
(Novagen) in 96-tube format as described for OmniMaxII
transformations with 1% w/v Glucose replacing the X-Gal
and IPTG reagents in the LB agar. All plates and sub-
sequent media used for the culture of the Rosetta(DE3)
LysS cells are identical to those described for B834(DE3)
cells but also supplemented with 35mg/ml chlorampheni-
col to maintain the pRareLysS plasmid. Plates were
incubated for 18h at 378C before individual colonies were
used to inoculate, 500ml GS96 (Bio101, QBioGene,
Cambridge, UK) supplemented with 0.05% v/v glycerol,
1% w/v glucose and 50mg/ml carbenicillin in 96-well deep-
well plates. The plates were sealed with gas-permeable
adhesive seals and shaken at 225r.p.m. at 378C for 18h.
For IPTG induction of expression, 50ml of each overnight
culture was then used to inoculate (in four 24-well deep-
well plates) 2.5ml of GS96 supplemented with 50mg/ml
carbenicillin. The diluted cultures were grown at 378C
with shaking at 225r.p.m., for 3h before reducing the
temperature to 208C, addition of ITPG to a ﬁnal
concentration of 0.5mM and shaking for a further 18h
at 208C. For auto-induction of expression, 50ml of each
overnight culture was used to inoculate (in four 24-well
deep-well plates) 2.5ml of Overnight Express
TM Instant
TB media (Novagen) supplemented with 50mg/ml carbe-
nicillin. The diluted cultures were grown at 378C with
shaking at 225r.p.m., for 3h before reducing the
temperature to 258C and shaking for a further 24h
at 258C.
A 1.5ml aliquot of culture from each well was then
transferred to a 2ml 96-well deep-well plate using a
Theonyx robot (Aviso Gmbh, Gera, Germany) and
harvested by centrifugation at 6000g for 10min at 48C
before decanting of the waste media. Pelleted cells were
frozen at  808C for at least 30min prior to screening
for soluble His6-tag protein expression using either the
Theonyx or BR8000 robotic platforms with standard
Qiagen Ni-NTA magnetic bead protocols (as per manu-
facturer’s instructions). Proteins puriﬁed by elution from
the Ni-NTA beads were analysed on SDS-PAGE gels
(Criterion
TM 10–20% gradient gels—Biorad, Hemel
Hempstead, UK or InVitrogen NuPAGE
TM Novex 10%
Bis-Tris Midi gels with MES buﬀer system) and visualized
with SafeStain
TM (InVitrogen). Scale-up and puriﬁcation
of proteins from E. coli were carried out as described
earlier (11).
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HEK 293T cells were maintained in DMEM (Sigma)
supplemented with 10% foetal calf serum (Sigma, Poole,
UK), 1  non-essential amino acids and 1mM glutamine
(InVitrogen). For expression screening, cells were seeded
in 24-well plates, at a density to give 75–80% conﬂuent
cells at the time of transfection, and transiently transfected
using GeneJuice (Novagen). The transfection protocol
was implemented on a Tecan EVO75 two-probe liquid
handling robot controlled by scripts written in-house
using the Tecan EVOWare software. The non-centric
pipetting capability of this robot was used throughout in
order to minimize disturbance of the cell monolayers
during reagent addition and aspiration. The liquid-
handling robot was contained in a Class 100 ﬂow cabinet
to maintain an aseptic environment for all of the robotic
manipulations that were performed at room temperature.
In brief,  1mg of individual mini-prepped plasmid DNAs
and 2ml of GeneJuice
TM (1.33mg/ml) were pre-incubated
for 30min in V-bottom well polypropylene micro-titre
plates in 60ml of DMEM (Sigma) supplemented with 1 
non-essential amino acids and 1mM glutamine
(InVitrogen). The DNA/GeneJuice cocktail was then
made up to 200ml with DMEM supplemented with 2%
foetal calf serum, 1  non-essential amino acids and 1mM
glutamine before addition to each well of the freshly
(robotically) aspirated cells. After 30min at room
temperature, the contents of each well are made up to
1ml by the addition of 800ml of DMEM supplemented
with 2% foetal calf serum, 1  non-essential amino acids
and 1mM glutamine before the plated cells are (manually)
returned to a 378C/5% CO2/95% air environment.
Secretion of protein into the media was analysed by
harvesting the culture media 96h post-transfection, and
running samples (10l) on SDS-PAGE. Following
transfer to PVDF membranes, His-tagged proteins were
detected by western blotting using an anti-His6 mono-
clonal antibody (clone BMG-His-1, Roche Diagnostics) in
combination with an anti-Mouse-Horse-Radish
Peroxidase secondary antibody (Pierce, Tattenhall, UK)
and ECL (GE Healthcare, Chalfont St.Giles, UK). The
expression of non-secreted/intracellular proteins was
analysed by washing of the adherent cells in PBS (1ml/
well) followed by addition of 200ml/well of NPI-10 (see
standard Qiagen Ni-NTA puriﬁcation protocol) supple-
mented with 1% v/v Tween 20 and 1000KUnits/ml
DNAse I (Sigma, Poole Dorset, UK). The plates were
shaken (on the Qiagen BioRobot8000) for 15min at
800r.p.m., subjected to a single freeze–thaw cycle (to
 808C), followed by shaking for a further 15min at
800r.p.m. shake, dilution in SDS-PAGE sample buﬀer
and analysis by western blotting as described for secreted
proteins.
Scale-up and puriﬁcation of proteins from HEK cells
was carried out as follows. Cells were grown in roller
bottles and transfected with plasmid DNA using poly-
ethylenimine (PEI), as previously described (7,12).
Secreted proteins were puriﬁed from the culture medium
using an automated protocol, written in-house, imple-
mented on an A ¨ KTA Xpress instrument (GE Healthcare,
Uppsala, Sweden), Brieﬂy, batches of media (100ml) were
passed through a 5ml HisTrap column (GE Healthcare,
Uppsala, Sweden) each followed by a 20ml wash of
50mM Tris-HCl, 500mM NaCl, 30mM imidazole, pH
7.5. This ‘batch loading’ methodology was adopted to
prevent components of the eukaryotic cell media displa-
cing the His-tagged protein of interest during the
processing of large sample volumes (J.N., unpublished-
data). This sequence was automatically repeated until all
the media had been loaded (completion of the loading was
detected by the integral air sensor), the column was
washed with a further 20ml of loading buﬀer, before
elution of bound proteins in 50mM Tris-HCl, 500mM
NaCl, 500mM imidazole, pH 7.5.The eluted protein peak
was automatically collected in a sample loop and
re-injected onto a pre-equilibrated HiLoad 16/60
Superdex 200 column (GE Healthcare, Uppsala,
Sweden). Protein was subjected to size exclusion chroma-
tography in 20mM Tris-HCl, 200mM NaCl, pH 7.5 and
fractions collected using a peak detection algorithm.
Fractions containing the protein of interest at 495%
pure by SDS-PAGE were pooled, quantiﬁed (by A280nm),
analysed by mass spectrometry and stored at 48C prior to
use.
Constructionofbaculovirusesandexpressionininsectcelllines
Sf9 cells were grown in Sf900 II-SFM media and plated in
24-well plates at a density of 2 105 cells per 400ml per
well, and incubated for a minimum of 1h prior to
transfection at 278C to allow attachment to the plate/
substrate. Adherent cells were then co-transfected on a
Tecan EVO75 two-probe liquid handling robot controlled
by scripts written in-house using the Tecan EVOWare
software. In Brief, 4ml (300–700ng) of each pOPIN
plasmid preparation (see Cloning section), 4ml linearized
Autographa californica bacmid (12), 4ml of Insect
GeneJuice
TM (Novagen) and 13ml of Sf900 II-SFM
media were mixed and then pre-incubated for 30min in
V-well polypropylene micro-titre plates before addition to
the adherent cell cultures. Primary viral stocks were
manually harvested from the supernatant at 120h post-
transfection and the remaining adherent cells were lysed
and analysed by SDS-PAGE and western blotting (as
intracellular targets in HEK cells—see previous section).
RESULTS
Vector design
A suite of versatile expression vectors has been con-
structed to enable the rapid cloning of PCR products
using the In-Fusion
TM enzyme. The mechanism of this
reaction has not been fully reported but relies on the
presence of homology between extensions on the PCR
product and the ends of a linearized vector; the optimal
length for these homologous sequences is around 15bp.
Once these homologous extensions have been incorpo-
rated into the PCR product, no further processing of
the insert is required prior to the In-Fusion
TM reaction
(a similarity with the Gateway
TM system, but in contrast
to PCR-LIC methods). By selection of the appropriate
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can be made incorporating either N- or C-terminal His6-
puriﬁcation tags for expression in E. coli, mammalian and
insect cells from a single cloning operation (see Table 1).
One feature of the In-Fusion
TM reaction is the removal of
any 30 overhangs generated by linearization of the vectors,
for example, the GTAC 30 overhang created by KpnI-
cleavage of the vectors is removed from the vector during
the In-Fusion reaction. This allows an eﬃcient restriction
enzyme to be used for linearization and the simple
re-constitution of the full 3C protease cleavage site
(LEVLFQ
Y
GP-cleavage site denoted by arrow) by the
addition of the last two bases of the glycine codon and the
whole proline codon into the appropriate primer exten-
sion. This property of the In-Fusion
TM enzyme is also
exploited to re-constitute the signal peptidase cleavage site
in the production of constructs for secreted products
(pOPING—see Table 1). To exemplify the utility of the
method described in this article, we report the results from
three case studies in which ﬁve pOPIN vectors have been
used for the parallel cloning and expression screening of
multiple genes or gene fragments. Automated liquid
handling steps have been implemented to produce a
scaleable and sustainable process amenable for high-
throughput operation. Typically, vector construction, and
PCR veriﬁcation, can be accomplished in three days and
subsequent expression screening takes between three and
ﬁve days depending upon whether E. coli, mammalian or
insect cells are used to express the proteins. Thus the
whole procedure can be carried out within two working
weeks. The target genes used in these case studies
are referred to by their construct number in the OPPF
target database and full details are given in Supplementary
Table 1.
Case study I: Expression of Neisseria transcription
factorsin E. coli
As part of a structural proteomics study of pathogenic
Neisseria, twenty transcriptional regulators were selected
from the annotated genomes of Neisseria meningitidis MC
58 (13) and Neisseria gonorrhoeae (unpublished data) for
cloning and expression screening in E. coli in order to
identify constructs suitable for protein production and
subsequent crystallization experiments. Primer tags were
selected to produce full-length constructs with either
N-terminal or C-terminal His6 tags. In addition sub-
domain versions of seven of the targets were designed with
N-His6 or C- His6 tags to give a total of forty-eight
constructs, thirty-one with N-His6 and seventeen with
C-His6 (see Supplementary Table 1 for details). Forty-
seven of the forty-eight Neisseria spp. gene sequences were
successfully ampliﬁed from genomic DNA templates and
the PCR products puriﬁed in a parallelized/HTP format
without any signiﬁcant losses. Puriﬁed PCR products were
cloned by In-Fusion
TM into either pOPINE or pOPINF
to add C-His6 or N-His6-3C site tags to the gene sequences
respectively. PCR screening of two clones for each
construct gave forty-two expression vectors that increased
to forty-four when a further two clones were analysed.
Therefore, the overall cloning eﬃciency (in terms of
construct coverage) after picking and testing four clones
was 92% with no diﬀerence observed in the cloning
eﬃciencies of pOPINE compared to pOPINF. The reason
that four of the ampliﬁed sequences did not clone in this
experiment is not clear, though the yield of two of the
PCR products was relatively low. Expression screening
of PCR veriﬁed clones in E. coli was carried out using
an automated procedure, with soluble proteins puriﬁed
at small-scale using Ni-NTA magnetic beads and analysed
by SDS-PAGE. The results showed that twenty-seven
of the forty-three expression vectors that had been
constructed gave soluble protein, though three of these
proteins ran at a lower molecular weight than expected
on SDS-PAGE (OPPF 3292, 3354, 3323, Figure 2).
Of the remaining vectors, no expression was detected in
either soluble or insoluble fractions of the induced
cultures (data not shown). All the vectors were sequence
veriﬁed to ensure that the lack of expression was not due
Figure 2. Expression of Neisseria sp. proteins from either pOPINE
(C-His6) or pOPINF (N-His6) in B834(DE3) E. coli. Plasmids were
transformed into B834(DE3) cells, expression was induced by the
addition of IPTG to the media and the resulting expression levels
assayed by a Ni-NTA robotic screen followed by SDS-PAGE. The lane
labels refer to unique OPPF identiﬁers (OPPF construct numbers; see
Supplementary Table 1) followed by N or C to indicate the position of
the His6 tag in the construct. The lane labelled ‘Low’ contains Low
Range Sigma Markers (M3913) and the lane labelled ‘High’ contains
High Range Sigma Markers (M3788), molecular marker masses are
indicated in kDa. Construct numbers labelled   were selected for scale-
up and puriﬁcation (Table 2).
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response regulator (LysR) family genes appeared to be
problematical, though interestingly, for the cysB gene,
expression of a C-His protein was observed whereas
no expression of the equivalent N-His construct
was detected (Figure 2, OPPF 3352 versus OPPF 3288).
This illustrates the value of producing both versions
in parallel.
To assess the yield of protein following puriﬁcation at
largescale, ten constructs were grown to one-litre culture
and puriﬁed using the semi-automated puriﬁcation pro-
tocol described in the Materials and methods section.
In all cases, the yields of puriﬁed protein were more
than suﬃcient for both functional and structural studies
with high yields obtained for both N-His-tagged and
C-His-tagged proteins in the range of 10–90 puriﬁed
protein mg/l culture (Table 2).
Case study II: Expression of human gene extra-cellular
constructsas secreted proteins in HEK 293T cells
Multiple constructs of the human and mouse gene,
KIAA0319, a cell surface glycoprotein recently associated
with developmental dyslexia (14) were designed on the
basis of bioinformatics analyses using the OPAL resource
of bioinformatics tools developed in-house (15). The
sequences were annotated with information on potential
regions of high disorder (16), signal peptides and
transmembrane domains/helices and twelve constructs
were designed to cover the majority of the gene sequences,
including domains and combinations thereof (see supple-
mentary Table 1 for details). These were then ampliﬁed
from both the human and mouse templates to give a total
of twenty-four PCR products, which were subsequently
cloned by In-Fusion
TM into the pOPING vector which
contains a resident secretion signal sequence. PCR screen-
ing of two clones for each construct gave twenty-one
expression vectors, which again was improved when a
further two clones were analysed, to give twenty-three
constructs cloned (96%). In this experiment, the In-
Fusion
TM reaction was capable of cloning PCR products
over a wide size range (450–2800bp products). One PCR
product that failed to clone was obtained in relatively low
yield that may explain the lack of success with this
construct. The pOPING plasmid mini-preparations were
used directly in the automated HEK293T transfection
protocol prior to detection by western blotting.
Expression and secretion into the medium of thirteen of
the twenty-four constructs was observed by western
blotting though the levels of expression appeared to vary
between constructs (Figure 3). To assess how immuno-
reactivity in the western blot screen related to the yield of
protein on scale-up, transient expression of a subset of
these constructs was carried out at one-litre culture scale.
These constructs were selected on the basis that they gave
the strongest signals in the western blot screen (Figure 3).
Following puriﬁcation, the yield of protein from these
constructs was measured by absorbance at 280nm using
extinction coeﬃcients calculated for each sequence. Four
Table 2. Yield of Neisseria proteins expressed in E. coli using pOPINE and pOPINF vectors
OPPF No Description Construct N or C
terminal His tag
Molecular weight
of protein including
His tag (D)
Yield (mg/l)
3286 4NMB0381_1 cysB 89–317aa N 27390 63
3352 4NMB0381_1 cysB Full length C 36224 10
3304 4NMB1049_1 transcriptional regulator 86–305aa N 26163 90
3307 4NMB0595_1 phoP 1–124aa N 15718 37
3308 4NMB0595_1 phoP 127–225aa N 13118 26
3309 4NMB0810_1 TetR family transcriptional regulator Full length N 26972 29
3313 4NMC1118_1 transcriptional regulator Full length N 17329 60
3356 4NMA1884_1 transcriptional regulator Full length C 27557 68
3355 4NMB0075 Full length N 85301 17
3331 4NMB1891 Full length N 13374 16
Figure 3. Expression of KIAA0319 proteins in HEK 293T cells using
the pOPING vector. Domain and multi-domain constructs were
screened for expression in HEK293T cells and subsequent secretion
into the cell media analysed using SDS-PAGE and western blotting as
described in the Materials and methods section. The lane labels refer to
unique OPPF identiﬁers (OPPF contruct numbers: see Supplementary
Table 1). The lane labelled BM contains the BenchMark
TM ladder
(InVitrogen 10747-012), molecular marker masses are indicated in kDa.
Construct numbers labelled   were selected for scale-up and puriﬁcation
(Table 3).
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 0.5mg/l culture, whereas one (OPPF 3502) yielded
0.2mg/l. (Table 3). With the exception of OPPF 3502,
these yields would be adequate for functional studies and
with the use of sub-microlitre crystallization trials suitable
for initial screening (17). Therefore, screening at small-
scale has successfully identiﬁed constructs that would be
suitable for further investigation.
Case study III: Comparative expression of viral andhuman
gene domainsas fusionproteins inE. coli, HEK 293T and
Sf9 cells
Five proteins (or domains thereof—see Supplementary
Table 1 for details) were selected for expression trials in
all three of the expression systems available and also
as three diﬀerent fusions, namely N-His-3C, N-His-GST
(Glutathione-S-Transferase)-3C and N-His-MBP
(Maltose Binding Protein)-3C) from pOPINF, pOPINJ
and pOPINM, respectively. These fusion partners have
been used extensively by structural genomics groups in
attempts to render proteins ‘soluble’ in E. coli (see review
(2)). A single batch of PCR product for each target was
produced with the appropriate In-Fusion extensions for
cloning into pOPINF. The products were puriﬁed and
cloned into pOPINF, pOPINJ and pOPINM (as described
in the ‘Cloning’ section) and the resulting, PCR and
sequence-veriﬁed, clones for each construct were then
expressed in the three available hosts. For reference,
‘null’pOPINJ, ‘null’pOPINM vectors (i.e. vector with no
target genes inserted) and eGFP in pOPINF were included
in these screens. Protein expression in E. coli was
evaluated using the Ni-NTA protocol, expression in
HEK293T and Sf9 cells was evaluated in total protein
samples by western blotting. The results demonstrate that,
overall, E. coli gave the best coverage for expression of the
ﬁve constructs in all three fusion formats (Figure 4
summarized in Table 4). The MBP fusions gave the
strongest signals in the western blot screen for expression
of the targets in both HEK293 and Sf9 cell, whereas the
N-His versions performed the poorest. Further studies
would be required to assess the solubility and character-
istics of these proteins after cleavage from these large
‘solubilizing’ fusion partners.
Although based on a limited test set of proteins, these
data demonstrate parallel, multiple host screening using
the pOPIN vectors and that, combining this with the
facility to generate diﬀerent fusion tag formats, provides
the strategy for subsequent scale-up experiments.
DISCUSSION
The In-Fusion
TM cloning method was originally devel-
oped to produce a common entry vector for a multi-vector
cloning system based on the cre-lox recombination
(Clontech). As shown here and by others (18) (and
Andrew Farmer: Clontech, personal communication),
the enzyme can be used in combination with any 15bp
homology region to enable ligation-independent cloning
of PCR products. We have exploited this property,
in combination with single and multiple promoter vectors,
to produce a simple and versatile system for expression
of recombinant proteins. We have incorporated the
method into a semi-automated pipeline for both vector
construction and expression screening using standard
laboratory liquid handling instruments. The pilot experi-
ments in 96-well format showed cloning eﬃciencies of
89% after two clones per target tested, with 94%
achievable with four clones tested, which we would
recommend to maximize cloning eﬃciency. The reason(s)
for some PCR products not cloning is not clear although
the quality and quantity of the input DNA appears to be
important. Over the last 12 months in the OPPF, we have
used In-Fusion
TM to construct a total of 661 vectors from
703 PCR products, an overall cloning eﬃciency of 94%.
These results compare favourably with data reported by
other HTP structural genomics consortia using either the
Gateway
TM recombinatorial system (e.g. 79% PCR
product to expression clone eﬃciency (19,20)) or ‘classical’
restriction enzyme and ligation-dependent methods (e.g.
87% (1)).
Multi-promoter vectors have been used to express
recombinant proteins in more than one host in parallel,
typically baculovirus-infected insect cells and E. coli e.g.
(21,22). Similarly, the pOPINE, pOPINF, pOPINJ or
pOPINM vectors based on pTriEx2 (Novagen) described
in this study can be used to survey expression in E. coli,
insect cells, and mammalian cells from a single vector,
which can be easily constructed in HTP mode with the
associated savings in time and resources. Transient
transfection of mammalian cells, notably COS7 and
HEK293, is widely used to investigate the expression
of eukaryotic proteins and can be readily scaled up for
production purposes (7,12,23,24). We describe the deriva-
tion and use of a secretion vector based on the pOPINF/
pTriEx2 vector backbone for the HTP expression of extra-
cellular proteins and domains. In addition, the expression
from single vector constructs in all three hosts (E. coli,
HEK293T and Sf9 cells) has been demonstrated for ﬁve
Table 3. Yield of KIAA0319 proteins expressed in HEK293T cells using the pOPING vector
OPPF No Description Construct N or C
terminal
His tag
Molecular weight
of protein including
His tag (D)
Yield (mg/l)
3490 Human KIAA0319 382–813aa C 47566 0.5
3492 Human KIAA0319 382–623aa C 27197 1.5
3502 Mouse KIAA0319 391–822aa C 47227 0.2
3504 Mouse KIAA0319 391–632aa C 27065 1.0
3506 Mouse KIAA0319 21–438aa C 46402 0.7
PAGE 9 OF 12 Nucleic Acids Research, 2007, Vol. 35, No. 6 e45target proteins. This ability to screen in multiple
hosts would enable rapid scale-up in the most appropriate
host (determined by small-scale screening) without
the necessity for additional rounds of sub-cloning.
The transient transfection protocol (HEK293 cells)
and co-transfection protocols (Sf9 cells), which make use
of a commercial transfection reagents, have both been
automated to enable consistent HTP operation for
functional/structural proteomic applications. As far as
we are aware, this is the ﬁrst report of such
implementations.
In summary, we have addressed the primary character-
istics we set for an improved strategy for HTP cloning as
follows:
(1) The ability to clone genes-encoding proteins, or
domains thereof, in a rapid and reliable parallel or
high-throughput (HTP) fashion. Cloning eﬃciencies
of490% have been achieved in a parallel 96-well plate
format using a generic vector in combination with the
In-Fusion
TM enzyme.
(2) The ability to accurately determine the ﬁnal con-
structs without the addition of extraneous/vector or
restriction-site-derived amino acids to the expressed
protein. A suite of vectors has been described which
make use of In-Fusion
TM cloning to precisely engineer
the expressed sequence, for example, introducing an
N-terminal His6 tag and 3C protease cleavage site
to enable removal of the tag during puriﬁcation.
The utility of this format has been exempliﬁed
(Case study I).
(3) The process must be versatile in terms of insert
sequence independence. Three case studies have been
described in which eighty-two expression vectors have
been produced from a variety of target genes using the
vector system (Case studies I, II, III).
A
B
C
Figure 4. (A) Expression of viral and human protein/protein domains
in Rosetta(DE3)LysS E. coli. Plasmids were transformed into
Rosetta(DE3)pLysS cells, expression was auto-induced in TB
Overnight Express
TM and the resulting expression levels assayed by a
Ni-NTA robotic screen, followed by SDS-PAGE. The lane labels refer
to unique OPPF identiﬁers (OPPF construct numbers; see
Supplementary Table 2) followed by the pOPIN vector name
(pOPINF contributes an N-His-3C site fusion to the protein of
interest, pOPINJ contributes an N-His-GST-3C site fusion to the
protein of interest and pOPINM contributes an N-His-MBP-3C site
fusion to the protein of interest). eGFP refers to enhanced GFP and
‘null’ refers to vector alone (i.e. vector with no target genes inserted),
pOPINJ and pOPINM will however express N-His-GST (29.5kDa) and
N-His-MBP (44.3kDa), respectively. The lane labelled ‘Low’ contains
Low Range Sigma Markers (M3913) and the lane labelled ‘High’
contains High Range Sigma Markers (M3788), molecular marker
masses are indicated in kDa. (B) Expression of viral and human
protein/protein domains in HEK293T cells. Plasmids were robotically
transfected into HEK293T cells and the resulting expression levels
assayed by a SDS-PAGE and western blotting as described in the
Materials and methods section. The lane labels are identical to panel A
except that the standard molecular weight markers are replaced with
marked positions of the BenchMark
TM ladder (InVitrogen 10747-012),
His-tagged molecular mass markers (masses in kDa) on the right.
(C) Expression of viral and human protein/protein domains in Sf9
cells. Plasmids were robotically co-transfected into HEK293T cells
with linearized A. californica bacmid and the resulting expression
levels assayed by a SDS-PAGE and western blotting as described in
the Materials and methods section. The lane labels are identical
to panel A except that the standard molecular weight markers are
replaced with marked positions of the BenchMark
TM ladder
(InVitrogen 10747-012), His-tagged molecular mass markers (masses
in kDa) on the right.
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rapid and cost-eﬀective vector construction. Vector
construction involves a single-step reaction that enables
the simple and rapid construction of vectors in parallel
using a 96-well plate format. Further, certain PCR
products are compatible with multiple fusion vector
formats (e.g. N-His, N-His-GST and N-His-MBP—
see examples in Case study III) thereby enabling cost-
eﬀective use of PCR primers.
(5) The constructs should be capable of expressing
proteins from multiple hosts, i.e. a single vector
capable of expression in E. coli, mammalian cell
lines (e.g. HEK293T cells) and insect cell lines
(e.g. Sf9 cells). By adapting a multi-promoter vector
a single cloning step has been used to produce a single
vector suitable for expression in E. coli, mammalian
and insect cells. The utility of this has been exempliﬁed
(Case study III).
(6) The expressed proteins must be capable of puriﬁca-
tion in HTP mode, i.e. they must all be fused to a
common aﬃnity puriﬁcation ‘tag’ which may be
removed, if desired, by enzymatic digest prior to
crystallization. All vectors, regardless of additional
fusion protein expressed, add either an N-terminal or
C-terminal His6 tag onto the expressed target protein
to facilitate detection and puriﬁcation. The puriﬁcation
of proteins expressed both intracellularly in E. coli and
secreted from mammalian cells using a common
puriﬁcation strategy has been exempliﬁed (Case
studies I and II).
(7) The process should be amenable to automation.
Laboratory automation to carry out liquid handling
tasks involved in the various stages of the expression
screening experiments in all three hosts has been
described.
SUPPLEMENTARY DATA
Supplementary Data is available at NAR online.
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